BrightGene Bio Medical Technology C Total Liabilities
BrightGene Bio Medical Technology C total liabilities. Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has total liabilities worth CN¥2.80 Billion CNY (≈ $409.38 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688166 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BrightGene Bio Medical Technology C (2016–2024)
Total liabilities of BrightGene Bio Medical Technology C from 2016 to 2024. This chart illustrates how BrightGene Bio Medical Technology C's total liabilities have evolved over time, based on quarterly financial data.
BrightGene Bio Medical Technology C Competitors by Total Liabilities
The table below lists competitors of BrightGene Bio Medical Technology C ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Twenty One Capital, Inc.
NYSE:XXI
|
USA | $108.82 Million |
|
Dongsuh
KO:026960
|
Korea | ₩63.60 Billion |
|
Extendicare Inc
TO:EXE
|
Canada | CA$1.15 Billion |
|
Lafarge Malayan Cement Bhd
KLSE:3794
|
Malaysia | RM3.95 Billion |
|
Boston Beer Company Inc
NYSE:SAM
|
USA | $335.62 Million |
|
DRDGOLD Limited
JSE:DRD
|
South Africa | ZAC3.36 Billion |
|
NBTM New Materials Group Co Ltd
SHG:600114
|
China | CN¥3.84 Billion |
|
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
|
China | CN¥1.23 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down BrightGene Bio Medical Technology C's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BrightGene Bio Medical Technology C assets under control.
Liquidity & Leverage Metrics
BrightGene Bio Medical Technology C Total Liabilities Ratios Explained
BrightGene Bio Medical Technology C total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BrightGene Bio Medical Technology C's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual total liabilities of BrightGene Bio Medical Technology C from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.73 Billion ≈ $399.04 Million |
+4.31% |
| 2023-12-31 | CN¥2.61 Billion ≈ $382.55 Million |
+8.05% |
| 2022-12-31 | CN¥2.42 Billion ≈ $354.06 Million |
+97.04% |
| 2021-12-31 | CN¥1.23 Billion ≈ $179.69 Million |
+210.70% |
| 2020-12-31 | CN¥395.23 Million ≈ $57.83 Million |
+265.24% |
| 2019-12-31 | CN¥108.21 Million ≈ $15.83 Million |
+2.55% |
| 2018-12-31 | CN¥105.52 Million ≈ $15.44 Million |
+33.76% |
| 2017-12-31 | CN¥78.89 Million ≈ $11.54 Million |
-51.91% |
| 2016-12-31 | CN¥164.05 Million ≈ $24.01 Million |
-- |
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more